How PSA Has Impacted the Use of ADT in Prostate Cancer

Video

Tia Higano, MD, FACP, provides a historical perspective on prostate cancer the use of androgen-deprivation therapy (ADT) and on prostate-specific antigen (PSA) in diagnosis and monitoring.

Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.
Ablative technology may generate an immune response that can be enhanced via injected immunotherapy in patients with solid tumors.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Related Content